Abstract: Described are cell-based methods for detecting botulinum neurotoxin (BoNT) potency and/or activity in the absence of LD50 assays that rely upon large numbers of laboratory animals.

Abstract: The present invention relates to a combination of ivermectin and brimonidine for use in the treatment and/or the prevention of moderate to severe rosacea, preferably by topical administration of a 1% ivermectin cream and 0.33% brimonidine gel.

Abstract: A method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include ester crosslinks formed as byproducts during the amide crosslinking; and ii) subjecting the crosslinked glycosaminoglycans to alkaline treatment to hydrolyze ester crosslinks formed as byproducts during the amide crosslinking.

Abstract: A process is described for preparing a stable emulsion that includes at least one avermectin. Also described, is the emulsion thus obtained, especially for use in the treatment of dermatological disorders such as rosacea.

Abstract: The present disclosure relates to compositions comprising hydrogels and solid particles and their use. More specifically, the proposed technique relates to methods for manufacturing of a composition comprising solid particles encapsulated within crosslinked polysaccharide molecules forming hydrogel particles, the method comprising mixing water-soluble polysaccharide molecules comprising one or more carboxyl groups, water insoluble solid particles, a di- or multinucleophilic functional crosslinker, and a coupling agent, in a water suspension at pH between 5 and 9, to form a composition comprising a hydrogel of crosslinked polysaccharide molecules encapsulating the solid particles. The disclosure comprises the composition, methods for producing the composition and use of the composition as a dermal filler.

Abstract: The present disclosure provides a method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules at a concentration Cfinal (mg/mL). The method comprising the steps of: a) crosslinking a glycosaminoglycan having a molecular weight of above 700 kDa in conditions so as to provide a glycosaminoglycan hydrogel crosslinked by amide bonds and having a Cmin (mg/mL) that is above Cfinal/2, wherein Cmin is the concentration of gel-form glycosaminoglycan in the gel when fully swollen in physiological buffer; b) subjecting the hydrogel from step a) to post-crosslinking degradation of the glycosaminoglycan backbone, thereby reducing the Cmin of the hydrogel to a value that is below Cfinal/2; and c) formulating the partially degraded hydrogel obtained from step b) to form an injectable hydrogel composition having a concentration of glycosaminoglycan molecules of Cfinal (mg/mL).

Abstract: A method for cleaving amide bonds, comprising: a) providing a molecule comprising an amide group; b) reacting the molecule comprising an amide group with hydroxylamine (NH2OH) or a salt thereof to cleave the amide bond of the amide group.

Abstract: A method for manufacturing a shaped cross-linked hyaluronic acid product including the step of subjecting a non-cross-linked precipitated hyaluronic acid substrate in a desired shape to a single cross-linking reaction in a liquid medium having a pH of 11.5 or higher and including one or more polyfunctional cross-linking agent(s) and an amount of one or more organic solvent(s) giving precipitating conditions for hyaluronic acid, under suitable conditions to obtain a precipitated, shaped cross-linked hyaluronic acid product having a degree of modification of 1-40 cross-linking agent units per 1000 disaccharide units.

Abstract: Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.

Abstract: Described are high molecular weight glycosaminoglycan (GAG) hydrogel compositions comprising GAGs covalently crosslinked with a carbohydrate crosslinker, and methods of making the high molecular weight GAG hydrogel compositions. Further described are methods of using the high molecular weight glycosaminoglycan (GAG) hydrogel compositions for reparative or plastic surgery, esthetic dermatology, facial contouring, body contouring, and gingival augmentation.

Abstract: A process for manufacturing a cross-linked hyaluronic acid (HA) gel product is comprising the steps of: (a) preparing an aqueous mixture of HA and a cross-linking agent selected from multiepoxides and diepoxides; wherein the HA is dissolved in an aqueous solution containing 1-10% (w/w) inorganic hydroxide; and wherein the dissolved HA constitutes more than 10% (w/w) of the final mixture; and (b) subjecting the aqueous mixture to cross-linking conditions to allow the dissolved HA to react with the cross-linking agent so as to obtain a cross-linked HA gel product.

Abstract: Described are ready-to-use injectable compositions comprising polymeric microspheres or microparticles of non-animal origin, a hydrogel comprising water and a cellulose-derivative gelling agent, and polysorbate 80. Further described are methods of using the ready-to-use injectable compositions for reparative or plastic surgery, esthetic dermatology, facial contouring, body contouring, and gingival augmentation.

Abstract: A hyaluronic acid product is comprising a cross-linked hyaluronic acid and one or more cyclodextrin molecules, and further comprising a guest molecule capable of forming a guest-host complex with the aminocyclodextrin molecule acting as a host, wherein the guest molecule is a retinoid, preferably adapalene, or a RAM BA. The hyaluronic acid is cross-linked by ether bonds, and the one or more cyclodextrin molecules are grafted onto the cross-linked hyaluronic acid by amide bonds, preferably using a triazine-based coupling reagent.

Abstract: A method for manufacturing a shaped cross-linked hyaluronic acid product including the step of subjecting a non-cross-linked precipitated hyaluronic acid substrate in a desired shape to a single cross-linking reaction in a liquid medium having a pH of 11.5 or higher and including one or more polyfunctional cross-linking agent(s) and an amount of one or more organic solvent(s) giving precipitating conditions for hyaluronic acid, under suitable conditions to obtain a precipitated, shaped cross-linked hyaluronic acid product having a degree of modification of 1-40 cross-linking agent units per 1000 disaccharide units.

Abstract: A micro- or nanoparticular vesicle comprises at least a crosslinked hyaluronic acid (HA), wherein the crosslinked hyaluronic acid is crosslinked by a chemical crosslinking agent, and wherein the degree of modification of said crosslinked hyaluronic acid with said chemical crosslinking agent is less than 1.9 mole %. Also disclosed are a method of manufacturing such vesicles, compositions comprising such vesicles and their uses.

Abstract: Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed.

Abstract: A method for cleaving amide bonds, including: a) providing a molecule including an amide group; b) reacting the molecule including the amide group with a hydroxylamine salt to cleave the amide bond of the amide group. The method may further include c) recovering a product formed by the reaction of step b).

Abstract: The present specification relates to a syringe comprising a barrel, a plunger moveably arranged within the barrel and a plunger rod for driving the plunger, and a mechanism for providing feedback to a user as the plunger rod is moved relative to the barrel for driving said plunger such that feedback is given to a user as the plunger rod is moved relative to the barrel for driving the plunger. The plunger rod is arranged to drive the plunger such that a predetermined relative movement between at least a portion of the plunger rod and the plunger is allowed. The present specification further relates to a plunger assembly wherein a predetermined relative movement between at least a portion of the plunger rod and the plunger is allowed.